Application 207318

Type: NDA
Sponsor: ACADIA PHARMS INC

Application Products#

Product, Drug, Ingredient table
Product	Drug	Ingredient	Form	Strength	Reference drug	Reference standard
001	NUPLAZID	PIMAVANSERIN TARTRATE	TABLET;ORAL	EQ 17MG BASE	Yes	No
002	NUPLAZID	PIMAVANSERIN TARTRATE	TABLET;ORAL	EQ 10MG BASE	Yes	Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
N207318-001	NUPLAZID	PIMAVANSERIN TARTRATE	EQ 17MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET / ORAL		RLD	2016-04-29
N207318-002	NUPLAZID	PIMAVANSERIN TARTRATE	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28

Orange Book patents#

Current patent rows page 1 of 1 · 14 matching rows.

Application-product, Patent, Expiration table
Application-product	Patent	Expiration	Use code	Coverage / status	Submission date
N207318-001	7659285	2026-08-24	U-1844		2016-05-25
N207318-001	7732615	2028-06-03		Drug substance, Drug product	2016-05-25
N207318-001	7732615*PED	2028-12-03		Pediatric extension
N207318-001	7601740	2030-04-29		Drug substance, Drug product	2016-05-25
N207318-001	7601740*PED	2030-10-29		Pediatric extension
N207318-002	7659285	2026-08-24	U-1844		2018-07-25
N207318-002	7732615	2028-06-03		Drug substance, Drug product	2018-07-25
N207318-002	7732615*PED	2028-12-03		Pediatric extension
N207318-002	7601740	2030-04-29		Drug substance, Drug product	2018-07-25
N207318-002	7601740*PED	2030-10-29		Pediatric extension
N207318-002	10517860	2037-03-23	U-1974		2020-01-10
N207318-002	10953000	2037-03-23	U-1974		2021-03-30
N207318-002	10517860*PED	2037-09-23		Pediatric extension
N207318-002	10953000*PED	2037-09-23		Pediatric extension

Orange Book exclusivity#

Current exclusivity rows page 1 of 1 · 4 matching rows.

Application-product, Exclusivity code, Expiration table
Application-product	Exclusivity code	Expiration
N207318-001	M-14	2029-04-27
N207318-001	PED	2029-10-27
N207318-002	M-14	2029-04-27
N207318-002	PED	2029-10-27

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 86 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Product TE source text	RLD / RS	Approval date	Source SHA-256
2026-09-14 22:38:34	2026-08	N207318-001	NUPLAZID	EQ 17MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET / ORAL		RLD	2016-04-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N207318-001	NUPLAZID	EQ 17MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET / ORAL		RLD	2016-04-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N207318-001	NUPLAZID	EQ 17MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET / ORAL		RLD	2016-04-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207318-001	NUPLAZID	EQ 17MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET / ORAL		RLD	2016-04-29	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N207318-001	NUPLAZID	EQ 17MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET / ORAL		RLD	2016-04-29	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N207318-001	NUPLAZID	EQ 17MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET / ORAL		RLD	2016-04-29	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N207318-001	NUPLAZID	EQ 17MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET / ORAL		RLD	2016-04-29	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N207318-001	NUPLAZID	EQ 17MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET / ORAL		RLD	2016-04-29	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N207318-001	NUPLAZID	EQ 17MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET / ORAL		RLD	2016-04-29	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N207318-001	NUPLAZID	EQ 17MG BASE	TABLET / ORAL		RLD	2016-04-29	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N207318-001	NUPLAZID	EQ 17MG BASE	TABLET / ORAL		RLD	2016-04-29	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N207318-001	NUPLAZID	EQ 17MG BASE	TABLET / ORAL		RLD	2016-04-29	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N207318-001	NUPLAZID	EQ 17MG BASE	TABLET / ORAL		RLD	2016-04-29	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N207318-001	NUPLAZID	EQ 17MG BASE	TABLET / ORAL		RLD	2016-04-29	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL	AB	RLD, RS	2018-06-28	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N207318-001	NUPLAZID	EQ 17MG BASE	TABLET / ORAL		RLD	2016-04-29	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL	AB	RLD, RS	2018-06-28	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N207318-001	NUPLAZID	EQ 17MG BASE	TABLET / ORAL		RLD	2016-04-29	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL	AB	RLD, RS	2018-06-28	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N207318-001	NUPLAZID	EQ 17MG BASE	TABLET / ORAL		RLD	2016-04-29	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N207318-001	NUPLAZID	EQ 17MG BASE	TABLET / ORAL		RLD	2016-04-29	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N207318-001	NUPLAZID	EQ 17MG BASE	TABLET / ORAL		RLD	2016-04-29	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	N207318-001	NUPLAZID	EQ 17MG BASE	TABLET / ORAL		RLD	2016-04-29	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N207318-002	NUPLAZID	EQ 10MG BASE	TABLET / ORAL		RLD, RS	2018-06-28	`74a2ff9319b5…`

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N207318-002	AB	1	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N207318-002	AB	1	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N207318-002	AB	1	`8072bd15b7f6…`
2024-03-16 18:09 UTC · 4 captures of this ZIP	2024-03	N207318-002	AB	1	`6a51e52b5d6a…`
2024-02-18 07:12 UTC	2024-02	N207318-002	AB	1	`1c564ffb4f44…`

Observed Orange Book patent history#

Patent history page 1 of 21 · 839 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Use code	Coverage / status	Submission date	Source SHA-256
2026-09-14 22:38:34	2026-08	N207318-001	7659285	2026-08-24	U-1844		2016-05-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-001	7732615	2028-06-03		Drug substance, Drug product	2016-05-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-001	7732615*PED	2028-12-03		Pediatric extension		`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-001	7601740	2030-04-29		Drug substance, Drug product	2016-05-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-001	7601740*PED	2030-10-29		Pediatric extension		`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-002	7659285	2026-08-24	U-1844		2018-07-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-002	7732615	2028-06-03		Drug substance, Drug product	2018-07-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-002	7732615*PED	2028-12-03		Pediatric extension		`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-002	7601740	2030-04-29		Drug substance, Drug product	2018-07-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-002	7601740*PED	2030-10-29		Pediatric extension		`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-002	10517860	2037-03-23	U-1974		2020-01-10	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-002	10953000	2037-03-23	U-1974		2021-03-30	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-002	10517860*PED	2037-09-23		Pediatric extension		`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-002	10953000*PED	2037-09-23		Pediatric extension		`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N207318-001	7659285	2026-08-24	U-1844		2016-05-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-001	7732615	2028-06-03		Drug substance, Drug product	2016-05-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-001	7732615*PED	2028-12-03		Pediatric extension		`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-001	7601740	2030-04-29		Drug substance, Drug product	2016-05-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-001	7601740*PED	2030-10-29		Pediatric extension		`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-002	7659285	2026-08-24	U-1844		2018-07-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-002	7732615	2028-06-03		Drug substance, Drug product	2018-07-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-002	7732615*PED	2028-12-03		Pediatric extension		`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-002	7601740	2030-04-29		Drug substance, Drug product	2018-07-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-002	7601740*PED	2030-10-29		Pediatric extension		`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-002	10517860	2037-03-23	U-1974		2020-01-10	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-002	10953000	2037-03-23	U-1974		2021-03-30	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-002	10517860*PED	2037-09-23		Pediatric extension		`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-002	10953000*PED	2037-09-23		Pediatric extension		`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N207318-001	7659285	2026-08-24	U-1844		2016-05-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207318-001	7732615	2028-06-03		Drug substance, Drug product	2016-05-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207318-001	7601740	2030-04-29		Drug substance, Drug product	2016-05-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207318-002	7659285	2026-08-24	U-1844		2018-07-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207318-002	7732615	2028-06-03		Drug substance, Drug product	2018-07-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207318-002	7601740	2030-04-29		Drug substance, Drug product	2018-07-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207318-002	10517860	2037-03-23	U-1974		2020-01-10	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207318-002	10953000	2037-03-23	U-1974		2021-03-30	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207318-001	7923564	2025-09-26		Drug substance, Drug product	2016-05-25	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207318-001	7659285	2026-08-24	U-1844		2016-05-25	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207318-001	7732615	2028-06-03		Drug substance, Drug product	2016-05-25	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207318-001	7601740	2030-04-29		Drug substance, Drug product	2016-05-25	`31067a03dcf5…`

Observed Orange Book exclusivity history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	Exclusivity code	Expiration	Source SHA-256
2026-09-14 22:38:34	2026-08	N207318-001	M-14	2029-04-27	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-001	PED	2029-10-27	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-002	M-14	2029-04-27	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207318-002	PED	2029-10-27	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N207318-001	M-14	2029-04-27	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-001	PED	2029-10-27	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-002	M-14	2029-04-27	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207318-002	PED	2029-10-27	`caaa826d4ba7…`
2019-12-13 00:20 UTC	2019-12	N207318-001	NCE	2021-04-29	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N207318-002	NCE	2021-04-29	`74a2ff9319b5…`
2021-12-28 21:50 UTC	2021-12	N207318-001	NCE	2021-04-29	`782e0a99824c…`
2021-12-28 21:50 UTC	2021-12	N207318-002	NCE	2021-04-29	`782e0a99824c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N207318-001	NCE	2021-04-29	`87673890dc5c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N207318-002	NCE	2021-04-29	`87673890dc5c…`
2021-03-12 10:30 UTC	2021-03	N207318-001	NCE	2021-04-29	`5aa47cf7b7d7…`
2021-03-12 10:30 UTC	2021-03	N207318-002	NCE	2021-04-29	`5aa47cf7b7d7…`
2020-12-22 03:56 UTC	2020-12	N207318-001	NCE	2021-04-29	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	N207318-002	NCE	2021-04-29	`8869cabd3fbd…`
2020-11-12 02:37 UTC	2020-11	N207318-001	NCE	2021-04-29	`c0c555d07b60…`
2020-11-12 02:37 UTC	2020-11	N207318-002	NCE	2021-04-29	`c0c555d07b60…`
2019-12-14 00:12 UTC	2019-12	N207318-001	NCE	2021-04-29	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N207318-002	NCE	2021-04-29	`3f01610625f2…`
2019-09-15 20:21 UTC	2019-09	N207318-001	NCE	2021-04-29	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N207318-002	NCE	2021-04-29	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	N207318-001	NCE	2021-04-29	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N207318-002	NCE	2021-04-29	`ea99ee380514…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N207318-001	M-14	2029-04-27	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N207318-001	PED	2029-10-27	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N207318-002	M-14	2029-04-27	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N207318-002	PED	2029-10-27	`a50c72e98297…`

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
NUPLAZID	PIMAVANSERIN TARTRATE	Acadia Pharmaceuticals Inc.	1e6bea44-57d6-4bac-9328-46e1ee59f83b	2026-06-18	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (NDA): 207318 application number: NDA207318 ndc (product): 63090-100

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 14 matching rows.

NDC, Name, Nonproprietary name table
NDC	Name	Nonproprietary name	Labeler	Marketing category	Status
63090-100	NUPLAZID	pimavanserin tartrate	ACADIA Pharmaceuticals In	NDA	Current
63090-100	NUPLAZID	pimavanserin tartrate	ACADIA Pharmaceuticals Inc	NDA	Current
63090-100	NUPLAZID	pimavanserin tartrate	ACADIA Pharmaceuticals Inc	NDA	Current
63090-100	NUPLAZID	pimavanserin tartrate	ACADIA Pharmaceuticals Inc	NDA	Current
63090-100	NUPLAZID	pimavanserin tartrate	Acadia Pharmaceuticals Inc.	NDA	Current
63090-100	NUPLAZID	pimavanserin tartrate	ACADIA Pharmaceuticals Inc	NDA	Current
63090-100	NUPLAZID	pimavanserin tartrate	Acadia Pharmaceuticals Inc.	NDA	Current
63090-100	NUPLAZID	pimavanserin tartrate	ACADIA Pharmaceuticals Inc	NDA	Current
63090-170	NUPLAZID	pimavanserin tartrate	ACADIA Pharmaceuticals In	NDA	Current
63090-170	NUPLAZID	pimavanserin tartrate	ACADIA Pharmaceuticals Inc	NDA	Current
63090-170	NUPLAZID	pimavanserin tartrate	ACADIA Pharmaceuticals Inc	NDA	Current
63090-170	NUPLAZID	pimavanserin tartrate	ACADIA Pharmaceuticals Inc	NDA	Current
63090-170	NUPLAZID	pimavanserin tartrate	ACADIA Pharmaceuticals Inc	NDA	Current
63090-170	NUPLAZID	pimavanserin tartrate	ACADIA Pharmaceuticals Inc	NDA	Current

Documents#

Document, Submission type, Date table
Document	Submission type	Date
85839	SUPPL	2026-05-05
85785	SUPPL	2026-05-01
80931	SUPPL	2026-05-01
81148	SUPPL	2025-02-07
75507	SUPPL	2023-09-18
75504	SUPPL	2023-09-18
65342	SUPPL	2020-11-25
65321	SUPPL	2020-11-25
60201	SUPPL	2019-10-02
60169	SUPPL	2019-10-01
58675	SUPPL	2019-05-14
58654	SUPPL	2019-05-13
57917	SUPPL	2019-03-07
57889	SUPPL	2019-03-05
55384	SUPPL	2018-09-05
54826	SUPPL	2018-07-06
54552	SUPPL	2018-06-14
54486	SUPPL	2018-06-08
53015	SUPPL	2018-03-15
53014	SUPPL	2018-03-15
52824	SUPPL	2018-03-06
52823	SUPPL	2018-03-06
50152	SUPPL	2017-10-23
50106	SUPPL	2017-10-19
44957	ORIG	2016-06-02
23034	ORIG	2016-06-02
40585	ORIG	2016-05-02
10614	ORIG	2016-05-02